An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia (PENNANT)
A Multi-center, Open-label Study to Assess the Effectiveness, Long-term Safety, Tolerability, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Sponsor: Karuna Therapeutics
Terminated
Company's business decision.
Listed as NCT05643170, this PHASE3 trial focuses on Schizophrenia and remains terminated or withdrawn. Sponsored by Karuna Therapeutics, it has been updated 7 times since 2022, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Apr 2023 — Aug 2023 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
▶ Show 2 earlier versions
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE3
First recorded
Nov 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Karuna Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .